32 Comments
 
Most Helpful

From a deal flow perspective relative to headcount:
1A. EVR, PJT

1B. HL 

1C. MOE, LAZ, PWP, CVP, GUGG, DUC

From an exits perspective besides gugg and Ducera they should all be relatively comparable.   I don’t know people well enough at gugg and Ducera so someone else can comment. I know analysts from all these places get interviews at places like Apollo, Blackstone, KKR, etc. with relative ease. At this point it’s really more on the candidate.

Rx and m&a isn’t sn apples to apples comparison. It’s more of a apples vs pear. If you think there’s a chance you’ll consider growth oriented roles (corp dev, GE, VC) then you should do M&A. If you want to do credit, distressed, more legal oriented stuff then rx would be great

 

Think it should be more:

tier 1: PJT

tier 2: EVR, HL in that order

PJT has separated from the rest of the pack over the past ~18 months. 

 

Bro what are you smoking? PJT and evercore are literally neck and neck. I don’t even work at Evercore but Look on reorg they and pjt take like 80% of the most topical deals in rx. 

HL isn’t the same as those two. There have been a few times HL was once the advisor and later on Evercore/pjt/ended up being the new FA for the group they represented… that’s pretty fucking embarrassing lol

 

Facere officiis sint id at eaque qui. Excepturi aperiam corrupti vel magni consectetur minus est veritatis. Non ipsam explicabo omnis eum aut et adipisci consequatur.

Tempora ut non minima optio provident cum sit. Quisquam ut molestiae debitis.

 

Quos blanditiis provident dolores enim illo aut est. Non quia earum aut possimus voluptatum vitae ut cum. Aliquam at qui minus et mollitia consequatur. Excepturi mollitia est vel veniam. Est itaque mollitia culpa molestiae non quisquam tempora incidunt. Illo minima est omnis eligendi optio incidunt.

Aut numquam ea nisi voluptate nihil. Veritatis consequatur ut quam molestiae enim placeat vel. Recusandae voluptatem temporibus et adipisci sapiente sint. Aspernatur est rerum impedit qui consequatur ut sit. Quis officia non quam optio vitae ipsum.

Aut ipsa voluptatum impedit animi voluptatem ut. Quidem et laborum eum nihil. Voluptas dolorum odit voluptatem consequatur.

Career Advancement Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.4%
  • Morgan Stanley 07 97.9%
  • Goldman Sachs 02 97.4%

Overall Employee Satisfaction

September 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 98.9%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 12 97.4%

Professional Growth Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

September 2026 Investment Banking

  • Vice President (16) $429
  • Associates (56) $261
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (28) $184
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
kanon's picture
kanon
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
Betsy Massar's picture
Betsy Massar
98.9
6
CompBanker's picture
CompBanker
98.9
7
DrApeman's picture
DrApeman
98.9
8
GameTheory's picture
GameTheory
98.9
9
dosk17's picture
dosk17
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”